Weekly issue 2026-W43 ·
Real-world epidemiology and renal outcomes of ADPKD in Türkiye: the PKD-TURK cohort
Plain language
Large national studies help show how autosomal dominant polycystic kidney disease (ADPKD) behaves in everyday clinical care across different regions. The PKD-TURK study looked back at records from 2,361 adults with ADPKD cared for at specialist nephrology centres across six regions of Türkiye between 2010 and 2025. Over a median follow-up of 6 years, about one in four patients had at least a 40% drop in kidney function (eGFR) and 10.5% reached kidney failure, with an average kidney-function loss of 3.33 mL/min/1.73 m² per year. Older age, high blood pressure, and higher Mayo imaging class were linked to faster kidney progression, while patients receiving tolvaptan had a lower risk of progression in this observational cohort.
Clinical note
Retrospective multicenter cohort study across six regions of Türkiye (BMC Nephrol; 2010–2025, n = 2,361 adults with ADPKD, mean age 38.6 ± 14 years, 51.8% female). Median province-level study-based prevalence was 3.86 per 100,000 (IQR 2.92–5.49), highest in the Black Sea region (13.46 per 100,000), increasing over time (annual percent change 14.4%, 95% CI 13.1–15.6, p < 0.001). Over a median 6-year follow-up, 23.9% had a ≥ 40% eGFR decline, 10.5% progressed to kidney failure (eGFR < 15 mL/min/1.73 m²), and median annual eGFR slope was -3.33 mL/min/1.73 m²/year. On Cox multivariable analysis, age (aHR 1.02, 95% CI 1.00–1.03, p = 0.010), hypertension (aHR 2.33, 95% CI 1.25–4.32, p = 0.007), and Mayo Imaging Classification (p = 0.027) predicted ≥ 40% eGFR decline, whereas tolvaptan use was associated with lower progression risk (aHR 0.56, 95% CI 0.37–0.85, p = 0.004). Observational hospital-based cohort.
Question for your next visit
How do my blood pressure and my Mayo imaging class affect my risk of kidney function decline?